We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00399438
Recruitment Status : Completed
First Posted : November 14, 2006
Last Update Posted : September 26, 2008
Information provided by:
Bristol-Myers Squibb

Brief Summary:
The primary purpose of this study is to evaluate the effects of BMS-562086 on small bowel and colonic transits in female subjects with diarrhea-predominant irritable bowel syndrome (D-IBS)

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome Drug: Placebo Drug: BMS-562086 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: A Dose-Ranging Study of the Pharmacodynamic Effects of BMS-562086 on Gastrointestinal Transit in Women With Diarrhea-Predominant Irritable Bowel Syndrome
Study Start Date : December 2006
Primary Completion Date : October 2007
Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea
U.S. FDA Resources

Arm Intervention/treatment
0 mg
Drug: Placebo
Tablets, Oral, once daily, 2 weeks
25 mg
Drug: BMS-562086
Tablets, Oral, once daily, 2 weeks
100 mg
Drug: BMS-562086
Tablets, Oral, once daily, 2 weeks

Primary Outcome Measures :
  1. Radioscintigraphy will be used to determine the effects of BMS-562086 on gastrointestinal transit [ Time Frame: taken at baseline on nominal study days 3,4, and 5 and post dose on nominal study days 14,15, 16 ]

Secondary Outcome Measures :
  1. Daily diary will be used to record the effects of BMS-562086 on bowel patterns and visceral symptoms. [ Time Frame: throughout the study ]
  2. Safety [ Time Frame: Safety labs at screening, nominal study days -3, 8, 15, 42, and 70 (discharge). ECGs will be taken at screening, nominal days 5 or 6, 14, and discharge. Vital signs will be taken at screening, on nominal days 3, 4, 5, 7, 8, 10, 11, 42 and discharge ]
  3. Blood pharmacokinetics [ Time Frame: PK samples will be taken on nominal days 8, 14 (serial: predose 0.5, 1, 2, 4, 6, 9 hours post dose), 15 (pre dose and 9 hours post dose), 16, 42 and discharge ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female subjects with D-IBS symptoms based on Rome II criteria and the subject's responses to the Bowel Disease Questionnaire

Exclusion Criteria:

  • Clinically significant prolonged diarrhea with dehydration requiring IV fluid within 60 days prior to baseline visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00399438

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Responsible Party: Study Director, Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00399438     History of Changes
Other Study ID Numbers: CN148-013
First Posted: November 14, 2006    Key Record Dates
Last Update Posted: September 26, 2008
Last Verified: September 2008

Keywords provided by Bristol-Myers Squibb:
Diarrhea-predominant irritable bowel syndrome

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Pathologic Processes
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases